Sabril (vigabatrin) is a medication indicated for the treatment of refractory complex partial seizures and infantile spasms. However, due to its potential severe adverse effects, strict adherence to the administration specifications is required.

Adverse Effects of Sabril (vigabatrin)

Adult Patients

Ophthalmological System: Blurred vision (13%), diplopia (7%), eye fatigue (2%).

Neurological System: Somnolence (22%), dizziness (24%), tremor (15%), memory impairment (7%).

Gastrointestinal System: Diarrhea (10%), nausea (10%), vomiting (7%).

General Reactions: Fatigue (23%), arthralgia (10%), weight gain (6%).

Pediatric Patients (Aged 2–16 Years)

Weight gain (15%), upper respiratory tract infection (15%), influenza (7%), and otitis media (6%) are relatively common in pediatric patients.

Patients with Infantile Spasms (IS)

Infants may experience somnolence (45%), bronchitis (30%), otitis media (10%), and acute otitis media (10%) after administration.

Severe Adverse Effects of Sabril (vigabatrin)

Permanent Visual Impairment

Risk Characteristics: Sabril may cause permanent bilateral concentric visual field constriction (including tunnel vision), which can lead to disability in severe cases. Some patients may develop central retinal damage and decreased visual acuity.

Monitoring Requirements: Visual function assessments should be performed at baseline (within 4 weeks after initiating treatment) and every 3 months thereafter. A follow-up assessment is required 3–6 months after drug discontinuation.

Abnormal MRI Findings in Infants

Manifestations: Approximately 22% of infants may present with abnormal MRI signals (e.g., symmetric hyperintensities in the thalamus and basal ganglia) after administration, which may be accompanied by motor abnormalities.

Other Severe Risks

Suicidal Tendency: Antiepileptic drugs may increase the risk of suicidal ideation or behavior; close monitoring of mood changes is required.

Peripheral Neuropathy: Adults may develop symptoms such as numbness of the extremities and decreased reflexes.

Precautions for Sabril (vigabatrin)

Drug Discontinuation and Administration Management

Sudden Discontinuation Prohibited: The dosage must be tapered gradually to avoid withdrawal seizures (including status epilepticus).

Dosage Form and Administration: Tablets may be taken with or without food. The powder for oral solution must be mixed with water and administered immediately. The provided special oral syringe should be used to accurately measure the dosage; household teaspoons are not allowed.

Drug Interactions: Sabril may moderately reduce the serum concentration of phenytoin; dosage adjustment of phenytoin should be considered based on clinical conditions. Concomitant use with clonazepam may increase the incidence of adverse reactions.